Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

ALKS - Alkermes plc Latest News | Finranks

Home

ALKS

A

Alkermes plc (ALKS)

NMS – Real Time Price. Currency in USD

29.39

-0.53 (-1.77%)

At close: Mar 27, 2026, 4:00 PM EDT

28.82

-0.57 (-1.94%)

After-hours: Mar 27, 2026, 5:11 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Why Is Alkermes (ALKS) Down 2.6% Since Last Earnings Report?

Why Is Alkermes (ALKS) Down 2.6% Since Last Earnings Report?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, 2026. This competitive grant program is designed to support research conducted by advanced practice nurses (APN), specifically licensed psychiatric-mental health nurse practitioners who are actively engaged in clinical, academic and/or community health center settings and who possess a commitment to a.

New Strong Sell Stocks for March 11th

New Strong Sell Stocks for March 11th

ALKS, BBSI and CBZ have been added to the Zacks Rank #5 (Strong Sell) List on March 11th, 2026.

Alkermes to Present at the Stifel 2026 Virtual CNS Forum

Alkermes to Present at the Stifel 2026 Virtual CNS Forum

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:30 a.m. ET (12:30 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in th.

Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change

Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change

ALKS beats Q4 earnings and revenue estimates, but shares fall 7%. The company announces a CEO transition plan.

Alkermes (ALKS) Reports Q4 Earnings: What Key Metrics Have to Say

Alkermes (ALKS) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates

Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates

Alkermes (ALKS) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $1.04 per share a year ago.

Videos

No Data

There is no data to display

Press releases

Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, 2026. This competitive grant program is designed to support research conducted by advanced practice nurses (APN), specifically licensed psychiatric-mental health nurse practitioners who are actively engaged in clinical, academic and/or community health center settings and who possess a commitment to a.

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. EST (1:00 p.m. GMT) today, to discuss these financial results an.

Alkermes plc Announces CEO Succession Plan

Alkermes plc Announces CEO Succession Plan

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) (Alkermes) today announced that Richard Pops will retire from his role as Chief Executive Officer (CEO), effective July 31, 2026. Alkermes' Board of Directors (the Board) appointed Blair Jackson, Alkermes' current Executive Vice President, Chief Operating Officer, as the company's next CEO, effective Aug. 1, 2026. Mr. Jackson is also expected to join the Board at that time. Following the transition, Mr. Pops will continue to serve as Chairman.

Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) (“Alkermes”) and Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel”) today announced Alkermes' completion of its acquisition of Avadel, a commercial-stage biopharmaceutical company. The acquisition adds Avadel's FDA-approved product, LUMRYZ®, to Alkermes' commercial portfolio, and provides Alkermes with a commercial organization experienced in this disease state. This strategic move accelerates Alkermes' entry into the sleep medicine market.